EFFECT OF TERBINAFINE, ITRACONAZOLE AND GRISEOFULVIN IN TINEA INFECTION MODIFIED BY STEROID USE

EVALUATION OF EFFICACY OF TERBINAFINE, ITRACONAZOLE AND GRISEOFULVIN IN PATIENTS WITH STEROID MODIFIED TINEA

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2023/06/053409

Enrollment

Registered

2023-06-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Terbinafine: Patients will be randomized into three groups comprising 30 participants in each group. All three drugs i.e, terbinafine, itraconazole and griseofulvin will be randomized i

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with clinically suspected lesions of tinea with positive microscopic examination with history of topical or systemic steroid use prior to study. 2.Patients of either sex, aged 18 -65 years 3.Willing to give written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women 2.Patients having clinical diagnosis of tinea infections other than tinea corporis, tinea cruris and tinea faciei. 3.History of use of antifungal drugs in past 4 weeks 4.History of known allergy to study drugs. 5.Patients with severe comorbidities: mental illness, liver and renal disease, cardiac failure and other co-existing dermatological diseases 6.Immunocompromised patients and patients on Immunosuppressive drugs during study duration or in past 2 weeks.

Design outcomes

Primary

Measure	Time frame
1.Percentage of subjects with clinical as well as mycological cure after 8 weeks of drug treatment with each of the three drugs. 2.Change in DLQI score before & after treatment with each of the three drugs. 3.Percentage of patients with different category of adverse drug reactions with each of the three drugs. Timepoint: 1.Percentage of subjects with clinical as well as mycological cure after 8 weeks of drug treatment with each of the three drugs. 2.Change in DLQI score before & after treatment with each of the three drugs. 3.Percentage of patients with different category of adverse drug reactions with each of the three drugs.	—

Measure

Time frame

1.Percentage of subjects with clinical as well as mycological cure after 8 weeks of drug treatment with each of the three drugs. 2.Change in DLQI score before & after treatment with each of the three drugs. 3.Percentage of patients with different category of adverse drug reactions with each of the three drugs. Timepoint: 1.Percentage of subjects with clinical as well as mycological cure after 8 weeks of drug treatment with each of the three drugs. 2.Change in DLQI score before & after treatment with each of the three drugs. 3.Percentage of patients with different category of adverse drug reactions with each of the three drugs.

—

Secondary

Measure	Time frame
2.Change in DLQI score before & after treatment with each of the three drugs. 3.Percentage of patients with different category of adverse drug reactions with each of the three drugs. Timepoint: 2.Change in DLQI score before & after treatment with each of the three drugs. 3.Percentage of patients with different category of adverse drug reactions with each of the three drugs.	—

Countries

India

Contacts

Public ContactDr Seema Jain

UCMS and GTB Hospital

dr.seemajain@gmail.com9910412070

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026